Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s40262-020-00891-1 http://scihub22266oqcxt.onion/10.1007/s40262-020-00891-1 32306288!7165255!32306288     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Pharmacokinet 2020 ; 59 (6): 659-669 Nephropedia Template TP {{tp|p=32306288|t=2020. Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties |pdf=|usr=}}{{32306288}} gab.com Text Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties JO: Clin Pharmacokinet http://www.kidney.de/pget.php?&tw=1&pmid=32306288 #FOAvip Since in vitro studies and a preliminary clinical report suggested the efficacy of chloroquine for COVID-19-associated pneumonia, there is increasing interest in this old antimalarial drug. In this article, we discuss the pharmacokinetics and safety of chloroquine that should be considered in light of use in SARS-CoV-2 infections. Chloroquine is well absorbed and distributes extensively resulting in a large volume of distribution with an apparent and terminal half-life of 1.6 days and 2 weeks, respectively. Chloroquine is metabolized by cytochrome P450 and renal clearance is responsible for one third of total clearance. The lack of reliable information on target concentrations or doses for COVID-19 implies that for both adults and children, doses that proved effective and safe in malaria should be considered, such as 'loading doses' in adults (30 mg/kg over 48 h) and children (70 mg/kg over 5 days), which reported good tolerability. Here, plasma concentrations were < 2.5 mumol/L, which is associated with (minor) toxicity. While the influence of renal dysfunction, critical illness, or obesity seems small, in critically ill patients, reduced absorption may be anticipated. Clinical experience has shown that chloroquine has a narrow safety margin, as three times the adult therapeutic dosage for malaria can be lethal when given as a single dose. Although infrequent, poisoning in children is extremely dangerous where one to two tablets can potentially be fatal. In conclusion, the pharmacokinetic and safety properties of chloroquine suggest that chloroquine can be used safely for an acute virus infection, under corrected QT monitoring, but also that the safety margin is small, particularly in children. Twit Text FOAVip Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties ????Clin Pharmacokinet http://www.kidney.de/pget.php?&tw=1&pmid=32306288 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32306288 #FOAvip English Wikipedia <ref>{{Cite pmid|32306288}}</ref> Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties #MMPMID32306288 Smit C; Peeters MYM; van den Anker JN; Knibbe CAJ Clin Pharmacokinet 2020[Jun]; 59 (6): 659-669 PMID32306288show ga Since in vitro studies and a preliminary clinical report suggested the efficacy of chloroquine for COVID-19-associated pneumonia, there is increasing interest in this old antimalarial drug. In this article, we discuss the pharmacokinetics and safety of chloroquine that should be considered in light of use in SARS-CoV-2 infections. Chloroquine is well absorbed and distributes extensively resulting in a large volume of distribution with an apparent and terminal half-life of 1.6 days and 2 weeks, respectively. Chloroquine is metabolized by cytochrome P450 and renal clearance is responsible for one third of total clearance. The lack of reliable information on target concentrations or doses for COVID-19 implies that for both adults and children, doses that proved effective and safe in malaria should be considered, such as 'loading doses' in adults (30 mg/kg over 48 h) and children (70 mg/kg over 5 days), which reported good tolerability. Here, plasma concentrations were < 2.5 mumol/L, which is associated with (minor) toxicity. While the influence of renal dysfunction, critical illness, or obesity seems small, in critically ill patients, reduced absorption may be anticipated. Clinical experience has shown that chloroquine has a narrow safety margin, as three times the adult therapeutic dosage for malaria can be lethal when given as a single dose. Although infrequent, poisoning in children is extremely dangerous where one to two tablets can potentially be fatal. In conclusion, the pharmacokinetic and safety properties of chloroquine suggest that chloroquine can be used safely for an acute virus infection, under corrected QT monitoring, but also that the safety margin is small, particularly in children. |*Drug Repositioning[MESH] |Adult[MESH] |Antimalarials/adverse effects/*pharmacokinetics/*therapeutic use[MESH] |COVID-19[MESH] |Child[MESH] |Chloroquine/adverse effects/*pharmacokinetics/*therapeutic use[MESH] |Coronavirus Infections/complications/*drug therapy[MESH] |Humans[MESH] |Malaria/drug therapy[MESH] |Pandemics[MESH]Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic(epmc).pdf DeepDyve Pubget Overpricing